The purpose of this study was to explore the correlation between the difference of Her-2 protein expression level in Her-2 positive breast cancer and the efficacy of neoadjuvant chemotherapy, so as to determine the best population for neoadjuvant treatment of Her-2 positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.